Apimeds Pharmaceuticals US, Inc. (APUS)

APUS Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	8.74	0	0.41	0.01	0.17
Cash & Short-Term Investments	8.74	0	0.41	0.01	0.17
Cash Growth	13694.21%	-99.16%	6551.77%	-96.40%	-
Prepaid Expenses	1.61	0.01	0.01	-	0
Total Current Assets	10.35	0.01	0.42	0.01	0.17
Total Assets	10.55	0.01	0.42	0.01	0.17
Accounts Payable	0.01	-	-	-	0.01
Accrued Expenses	0.07	0.7	0.12	0.04	-
Short-Term Debt	0.5	0.33	-	0.28	-
Current Income Taxes Payable	-	-	-	0	-
Total Current Liabilities	0.81	1.02	0.12	0.32	0.01
Long-Term Debt	-	0.35	0.27	0.4	0.4
Total Liabilities	0.81	1.37	0.39	0.72	0.41
Common Stock	0.13	0.08	0.08	0.1	0.1
Additional Paid-In Capital	17.07	2.95	2.95	1.41	1.22
Retained Earnings	-7.46	-4.39	-3	-2.22	-1.56
Shareholders' Equity	9.74	-1.36	0.03	-0.71	-0.24
Total Liabilities & Equity	10.55	0.01	0.42	0.01	0.17
Total Debt	0.5	0.67	0.27	0.68	0.4
Net Cash (Debt)	8.24	-0.67	0.14	-0.68	-0.23
Net Cash Per Share	0.97	-0.08	0.03	-0.18	-0.06
Filing Date Shares Outstanding	12.58	8.19	7.9	5.77	3.85
Total Common Shares Outstanding	12.58	7.9	7.9	5.77	3.85
Working Capital	9.54	-1.01	0.3	-0.31	0.16
Book Value Per Share	0.77	-0.17	0.00	-0.12	-0.06
Tangible Book Value	9.74	-1.36	0.03	-0.71	-0.24
Tangible Book Value Per Share	0.77	-0.17	0.00	-0.12	-0.06

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q